Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,473Revenue $M13.4Net Margin (%)-713.7Z-Score63.2
Enterprise Value $M1,898EPS $-3.4Operating Margin %-717.1F-Score2
P/E(ttm))0Cash Flow Per Share $-1.4Pre-tax Margin (%)-713.3Higher ROA y-yN
Price/Book3.810-y EBITDA Growth Rate %0Quick Ratio34.1Cash flow > EarningsY
Price/Sales2215-y EBITDA Growth Rate %0Current Ratio34.1Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-21.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-22.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M33.0ROI % (ttm)-27.3Gross Margin Increase y-yN

Gurus Latest Trades with GEVA

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GEVAGeorge Soros 2013-12-31 Sold Out -0.01%$45.51 - $69.69
($59.17)
$ 75.2427%Sold Out0
GEVAGeorge Soros 2013-09-30 Buy 0.01%$43.26 - $62.55
($49.11)
$ 75.2453%New holding, 17700 sh.17,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GEVA is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


GEVA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Williams GlenSVP, Technical Operations 2014-06-25Sell700$108.02-30.35 view
Quart Barry DDirector 2014-06-20Sell1,375$100-24.76 view
Quart Barry DDirector 2014-06-17Sell1,000$90-16.4 view
Quart Barry DDirector 2014-06-12Sell1,000$83.31-9.69 view
Goldberg Mark AlanEVP, Medical & Reg. Strategy 2014-06-11Sell21,597$80-5.95 view
BOESS CARSTENSVP, CFO 2014-05-16Sell9,927$81.94-8.18 view
Quinn AnthonyEVP, CMO & Head of R&D 2014-04-01Sell20,000$83.53-9.92 view
Heberlig ChrisGroup Vice President, Finance 2014-03-12Sell7,670$98.56-23.66 view
BAKER FELIXDirector, 10% Owner 2014-03-06Buy375,000$105.75-28.85 view
BAKER JULIANDirector, 10% Owner 2014-03-06Buy375,000$105.75-28.85 view

Press Releases about GEVA :

    Quarterly/Annual Reports about GEVA:

    News about GEVA:

    Articles On GuruFocus.com

    More From Other Websites
    Nasdaq stocks posting largest percentage decreases Jul 24 2014
    Synageva Shares Tumble Amid Positive Phase 3 Data, A Director's 75% Gain & Analyst Concerns Jul 02 2014
    Synageva's Sebelipase Alfa Meets Primary Endpoint in ARISE Jul 01 2014
    Synageva sinks as analysts express caution after trial data Jul 01 2014
    Synageva BioPharma™ Reports Positive Top-Line Results From Phase 3 Study Of Sebelipase Alfa In... Jun 30 2014
    SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 30 2014
    Synageva Phase 3 ARISE trial met primary endpoint Jun 30 2014
    Synageva BioPharma™ Reports Positive Top-Line Results From Phase 3 Study Of Sebelipase Alfa In... Jun 30 2014
    Synageva BioPharma™ Reports Positive Top-Line Results From Phase 3 Study Of Sebelipase Alfa In... Jun 30 2014
    Synageva BioPharma™ Reports Positive Top-Line Results From Phase 3 Study Of Sebelipase Alfa In... Jun 30 2014
    4:02 pm Synageva BioPharma reports positive top-line results from Phase 3 study of sebelipase alfa... Jun 30 2014
    SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 09 2014
    Synageva BioPharma™ Highlights Data Presentations And Satellite Symposium At The European... Jun 03 2014
    Synageva Biopharma™ To Present At The Jefferies And Goldman Sachs Healthcare Conferences May 28 2014
    SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 15 2014
    SYNAGEVA BIOPHARMA CORP Financials May 09 2014
    Synageva BioPharma™ Announces Satellite Symposium at the National Lipid Association Meeting May 02 2014
    SYNAGEVA BIOPHARMA CORP Files SEC form 10-Q, Quarterly Report May 01 2014
    Synageva's Q1 Loss Narrower than Expected May 01 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide